Research Article

Long Noncoding RNA *EZR-AS1* Regulates the Proliferation, Migration, and Apoptosis of Human Venous Endothelial Cells via SMYD3

Ganhua You,1,2 Xiangshu Long,2,3 Fang Song,3 Jing Huang,1,3 Maobo Tian,3 Yan Xiao,3 Shiyan Deng,3 and Qiang Wu3

1Guizhou University School of Medicine, No. 2708 South Section of Huaxi Avenue, Guiyang 550025, China
2Guizhou Institute for Food and Drug Control, No. 142 Shibei Road, Guiyang 550004, China
3Department of Cardiology, Guizhou Provincial People’s Hospital, People’s Hospital of Guizhou University, No. 83 Zhongshan East Road, Guiyang 550002, China

Correspondence should be addressed to Qiang Wu; wqgz0851@126.com

Received 30 December 2019; Accepted 25 February 2020; Published 27 May 2020

Academic Editor: Bo Zuo

Copyright © 2020 Ganhua You et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Numerous studies have shown that long noncoding RNAs (lncRNAs) play essential roles in the development and progression of human cardiovascular diseases. However, whether lncRNA ezrin antisense RNA 1 (*EZR-AS1*) is associated with the progression of coronary heart disease (CHD) remains unclear. Accordingly, the aim of the present study was to evaluate the role of lncRNA *EZR-AS1* in patients with CHD and in human venous endothelial cells (HUVECs). The findings revealed that lncRNA *EZR-AS1* was highly expressed in the peripheral blood of patients with CHD. *In vitro* experiments showed that the overexpression of *EZR-AS1* could enhance proliferation, migration, and apoptosis by upregulating the expression of EZR in HUVECs; downregulation of lncRNA *EZR-AS1* resulted in the opposite effect. lncRNA *EZR-AS1* was also found to regulate SET and MYND domain-containing protein 3 (SMYD3), a histone H3 lysine 4-specific methyltransferase, which subsequently mediated EZR transcription. Collectively, these results demonstrate that lncRNA *EZR-AS1* plays an important role in HUVECs function via SMYD3 signaling.

1. Introduction

As a result of economic development and an aging population, the risk of developing cardiovascular disease has gradually increased [1, 2]. Coronary heart disease (CHD) is a common, high rate of mortality disease with global influence [3, 4], and it is therefore necessary to optimize treatment and prevention strategies.

Long noncoding RNAs (lncRNAs) are a class of RNA molecules > 200 nucleotides in length, which do not encode proteins [5, 6]. lncRNAs regulate gene expression through epigenetic, transcriptional, and post-transcriptional mechanisms. Recent studies have shown that lncRNAs are also involved in the development and progression of various cardiovascular diseases [7–11], including heart failure, myocardial hypertrophy, heart metabolic disease, myocardial infarction, and atherosclerosis (AS).

Ezrin (EZR) is a member of the ezrin-radixin-moesin (ERM) family of cytoskeletal proteins, which connects the actin cytoskeleton to the plasma membrane. EZR plays a vital role in numerous processes associated with normal cell growth, including adhesion, cell polarity, and migration [12, 13]. SET and MYND domain-containing protein 3 (SMYD3), a histone H3 lysine 4-specific methyltransferase, which subsequently mediated EZR transcription. Collectively, these results demonstrate that lncRNA *EZR-AS1* plays an important role in HUVECs function via SMYD3 signaling.
binding sites, which present in the downstream of the EZR promoter, causing local accumulation of SMYD3 and accompanied H3K4Me3 at the EZR gene [16]. IncRNA EZR antisense RNA 1 (EZR-AS1) is 362 bp in length and is located on chromosome 6q25.3. The expression of EZR-AS1 may promote cell migration and mediate cancer cell differentiation [17]. Despite these discoveries, the role of IncRNA EZR-AS1 in noncancerous pathologies, particularly cardiovascular diseases, remains unclear.

Therefore, the aim of the present study was to determine the function of EZR-AS1 in CHD, by assessing the proliferation, migration, and apoptotic rates of human venous endothelial cells (HUVECs) following the knockdown and overexpression of IncRNA EZR-AS1.

2. Materials and Methods

2.1. Clinical Blood Samples. In the present study, 35 patients (24 men and 11 women; 50-75 years of age) were recruited, who had been angiographically diagnosed with CHD at the Guizhou Provincial People’s Hospital (Guiyang, Guizhou, China) between June 2018 and August 2018. In addition, 38 individuals without CHD (22 men and 16 women; 50-75 years of age) were enrolled as controls. The inclusion criteria included patients with (i) unstable angina or myocardial infarction; (ii) CHD complicated with other organic heart diseases; (iii) CHD combined with severe liver disease, kidney diseases, familial hypercholesterolemia, malignant tumors, or inflammatory diseases; and (iv) CHD combined with severe liver disease.

2.2. Cell Culture and Transfection. HUVECs were purchased from the Xiangya Cell Bank of Central South University. The cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (HyClone; GE Healthcare Life Sciences) supplemented with 10% fetal bovine serum (Biological Industries) and 1% penicillin/streptomycin (Beijing Solarbio Science & Technology Co., Ltd.), at 37°C (5% CO2). Cells in the logarithmic phase were harvested for further experimentation. The HUVECs were transiently transfected with negative control small interfering (si) RNA (si-control) or si-EZR-AS1; the pcDNA-control, pcDNA-EZR-AS1, pcDNA-EZR, or pcDNA-SMYD3; si-EZR-AS1+pcDNA-EZR; or si-EZR-AS1+pcDNA-SMYD3 as appropriate. Transfection was carried out with 50 nM siRNA or 1.6 μg/ml pcDNA using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. When simultaneously transfecting siRNA and pcDNA, 50 nM siRNA and 1.6 μg/ml pcDNA were also used. The sequences of the siRNAs are as follows: si-EZR-AS1, 5′-UAAUUUUCGUAUC UUUUCCCTT-3′; si-SMYD3, 5′-UCACAGCUUGACCC CAACTT-3′; and si-EZR, 5′-GCUCAAAGAUAAUUGCA UGTTT-3′.

2.3. Cell Counting Kit-8 (CCK-8) Assay. HUVECs were seeded into 96-well culture plates at a density of 3 × 10^3 cells/well. The following day, the HUVECs were transfected with the corresponding siRNAs or overexpression pcDNA for 24, 48, and 72 h. Cell viability was assessed using the CCK-8 assay (Dojindo Molecular Technologies, Inc.) according to the manufacturer’s protocol; 10 μl CCK-8 solution was added to each well, and the plates were incubated for 2 h. The absorbance was then measured at 450 nm using a plate reader.

2.4. Wound Healing Assay. HUVECs were plated in 6-well culture plates, and 48 h after transfection, the cell monolayers were scratched with a 200 μl plastic pipette tip. After washing twice with phosphate-buffered saline (PBS), the cells were incubated for 24 h in low-serum medium. The wound closure distance was then determined using an inverted microscope (Olympus Corporation) at ×100 magnification, and the area of closure between the 0 and 24 h time points was calculated.

Figure 1: Expression of IncRNA EZR-AS1 and EZR in peripheral blood. Reverse transcription-quantitative PCR was used to detect the expression levels of (a) IncRNA EZR-AS1 and (b) EZR in the peripheral blood of control subjects and patients with CHD. All results were expressed as mean ± SD. **P < 0.01 vs. controls.
**Figure 2:** Effects of IncRNA EZR-AS1 on human venous endothelial cell proliferation, migration, and apoptosis. Cells were transfected with (a) IncRNA si-EZR-AS1 (knockdown) or si-control and with pcDNA-EZR-AS1 (overexpression) or pcDNA-control. Untreated cells were used as a control. Posttransfection with si-EZR-AS1 or pcDNA-EZR-AS1, (b) viability, (c, d) migratory ability, and (e) apoptotic rates of the cells were detected by CCK-8 assay, wound healing assay, Transwell assay, and flow cytometry, respectively. Wound healing was quantified, and the number of migratory cells was counted. Magnification, ×100 (migration). All results were expressed as mean ± SD. *P < 0.05 and **P < 0.01 vs. si-control; #P < 0.05 and ##P < 0.01 vs. pcDNA-control.
2.5. Transwell Assay. The cells (5 × 10^4/plate) were resus- pended in 0.1 ml serum-free culture medium and seeded into the upper chamber of a Transwell insert (8 μm pore size, 24- well; Corning Inc.). In the lower chamber, 0.8 ml complete culture medium was added as a chemoattractant. Following incubation at 37°C for 48 h, the cells that had migrated to the lower surface were fi- xed with methanol for 20 min and then stained with 0.1% crystal violet solution for a further 20 min. Finally, the stained cells were counted under an inverted microscope (Olympus Corporation) at ×100 magnification.

2.6. Flow Cytometry. HUVECs were cultured in 6-well plates to 70-90% confluence. The cells were then digested using trypsin and collected by centrifugation (1000 rpm at 4°C for 5 min). Following two washes with precool PBS, the cells were collected and resuspended in 500 μl binding buffer (1X); 5 μl Annexin V-APC and 5 μl 7-AAD (Nanjing KeyGen Biotech Co., Ltd.) were added, and the cells were incubated at room temperature in the dark for 15 min. Apoptotic cells were then analyzed using a FACScan flow cytometer (BD Biosciences).

2.7. Reverse Transcription-Quantitative PCR (RT-qPCR). The extraction of RNA from the peripheral blood samples was conducted using Total RNA Extraction Kit of blood according to the manufacturer’s instructions (BioTeke Corporation). Total RNA was isolated from cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The RNA was then reverse transcribed into first-strand cDNA using the PrimeScript RT Reagent Kit (Takara Bio, Inc.), and the expression levels of the target RNA were determined.
by RT-qPCR analysis using the Two-Step SYBR PrimeScript RT-PCR Kit (Takara Bio, Inc.) on an Illumina P05775 system (Illumina, Inc.). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the normalization control, and the thermocycling conditions were as follows: one cycle at 95°C for 1 min; 40 cycles at 95°C for 15 sec and 60°C for 1 min; and one cycle at 95°C for 15 sec, 60°C for 1 min, and 95°C for 15 sec. The primers were supplied by Sangon Biotech Co., Ltd., and the sequences are as follows: lncRNA EZR-AS1, forward 5′-CCAATGAAGCCTCTCCCGTC-3′ and reverse 5′-GGGAGATAACAGGCCCTGAC-3′; EZR, forward 5′-GTGTGGTACTTTGGCCTCCA-3′ and reverse 5′-AACTTGGCCCGGAACTTGAA-3′; SMYD3, forward 5′-CCCTCGGGCGTACGTG-3′ and reverse 5′-CTTGGGGTGAACTTTT-3′; and GAPDH, forward 5′-AGC CACATCGCTCAGACAC-3′ and reverse 5′-GGCCCAATCC-3′. Relative gene expression was calculated using the 2^−ΔΔCq^ method [18].

2.8. Western Blotting. HUVECs were seeded into 6-well cell culture plates and incubated at 37°C overnight. The following day, the cells were transfected with the corresponding siRNAs or overexpression pcDNA. Radioimmunoprecipitation assay buffer (Beijing Solarbio Science & Technology Co., Ltd.) supplemented with complete protease inhibitor cocktail (Roche Molecular Diagnostics) was used to lyse the cells, and the protein concentration was quantified using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). 40 μg of protein extract was separated by SDS-PAGE (using 10 or 12% gels) and transferred to polyvinylidene fluoride membranes (EMD Millipore). The membranes were blocked for 2 h with 5% nonfat milk (at room temperature) and then incubated with primary antibodies at 4°C overnight. The membranes were subsequently washed with TBST (0.1% Tween 20) and then incubated with the secondary antibody (cat. no. bs-40296G-HRP; 1:5,000; BIOSS) for 1.5 h at room temperature. An enhanced chemiluminescence kit (EMD Millipore) was used to visualize the blots, and the protein bands were quantified using ImageJ 180 software (National Institutes of Health). The primary antibodies used in the present study were as follows: anti-SMYD3 (cat. no. 12859; 1:1,000), anti-EZR (cat. no. 3145; 1:1,000), anti-phosphatase and tensin homolog (PTEN; cat. no. 9188;
Figure 5: Continued.
assay showed that EZR-AS1 efficiency is illustrated in Figure 2(a). The results of the CCK-8 assay on EZR-AS1 (Figure 2(b)). Additionally, siRNA reverses EZR-AS1 migration (Figures 2(c) and 2(d)) and apoptosis (Figure 2(e)) in HUVECs.

To determine the effects of lncRNA EZR-AS1 on the Expression Levels of Apoptosis-Related Proteins in HUVECs. Initially, RT-qPCR was used to analyze the expression of EZR-AS1 and EZR in the peripheral blood of 35 patients with CHD and 38 control subjects. The results revealed that EZR-AS1 expression was markedly upregulated in patients with CHD, compared with the controls (Figure 1(a)). Similarly, EZR expression was also elevated in patients with CHD (Figure 1(b)).

Figure 5: Effects of pcDNA-EZR on human venous endothelial cells. After transfected with pcDNA-EZR or si-EZR-AS1+pcDNA-EZR, the (a) mRNA and (b) protein expression levels of EZR were determined using reverse transcription-quantitative PCR and Western blotting. The (c) viability, (d, f) migratory ability, and (e, g) apoptosis of cells were detected using the CCK-8 assay, wound healing assay, and flow cytometry, respectively. Wound healing was quantified. Magnification, ×100 (migration). All results were expressed as mean ± SD. *P < 0.05 and **P < 0.01 vs. si-control. #P < 0.05 and ##P < 0.01 vs. pcDNA-control. &P < 0.05 and &&P < 0.01 vs. pcDNA-EZR.

3.2. EZR-AS1 knockdown reduced cell viability (Figure 2(b)). Additionally, si-EZR-AS1 suppressed the migration (Figures 2(c) and 2(d)) and apoptosis (Figure 2(e)) of HUVECs. Overexpression of EZR-AS1 resulted in the reverse effect.

3.3. Functions of EZR-AS1 on Proliferation, Migration, and Apoptosis in HUVECs. To explore the functions of EZR-AS1 in HUVECs, the cells were transfected with siRNA or overexpression pcDNA of EZR-AS1; transfection efficiency is illustrated in Figure 2(a). The results of the CCK-8 assay showed that EZR-AS1 knockdown reduced cell viability (Figure 2(b)). Additionally, si-EZR-AS1 suppressed the migration (Figures 2(c) and 2(d)) and apoptosis (Figure 2(e)) of HUVECs. Overexpression of EZR-AS1 resulted in the reverse effect.

3.4. lncRNA EZR-AS1 Positively Regulates SMYD3 and EZR Expression. The expression levels of SMYD3 and EZR were analyzed via lncRNA EZR-AS1 knockdown or overexpression. The results showed that the downregulation of EZR-AS1 decreased the expression of SMYD3 and EZR, and the opposite effect was observed when EZR-AS1 was overexpressed (Figures 3(a)–3(e)). These data indicate that downregulating the expression of lncRNA EZR-AS1 inhibits apoptosis in HUVECs.

3.5. Overexpression of EZR Reverses the Effects of EZR-AS1 Knockdown on the Biological Properties of HUVECs. To further explore whether EZR was involved in the effects of si-EZR-AS1, HUVECs were transfected with an EZR overexpression pcDNA. RT-qPCR and Western blotting confirmed that the EZR expression level was significantly decreased in cells transfected with both si-EZR-AS1 and pcDNA-EZR (Figures 5(a) and 5(b)), compared with those transfected with pcDNA-EZR alone. Proliferation, migration, and apoptotic capacity were evaluated after transfection; the results showed that the overexpression of EZR significantly reversed the effects of si-EZR-AS1 on cell proliferation, migration, and apoptosis (Figures 5(c)–5(g)).
Relative mRNA expression (fold change)

- SMYD3
- EZR
- GAPDH

Relative protein expression (fold change)

Cell viability (OD)

Figure 6: Continued.
Vascular endothelial cells are important components of the vascular wall. The abnormal proliferation and migration of vascular endothelial cells are important pathophysiological processes in diseases such as CHD, hypertension, and restenosis after percutaneous coronary intervention [24–26]. In the present study, the role of EZR-AS1 was evaluated in HUVECs by assessing cell proliferation, migration, and apoptosis; this was achieved by transfection with si-EZR-AS1 or an overexpression pcDNA. The results revealed that the downregulation of EZR-AS1 significantly inhibited HUVECs proliferation, migration, and apoptosis; the opposite effects were observed following EZR-AS1 overexpression. These findings suggest that lncRNA EZR-AS1 influences the malignant behaviors of HUVECs, providing a basis for its therapeutic application in CHD.

EZR, encoded by Vil2, was identified as the first member of the ERM family. EZR is upregulated in a number of diseases, such as breast and cervical cancer, and overexpression of the EZR gene may enhance the metastatic capacity of tumors [27, 28]. Although the function of EZR has been extensively studied, the transcriptional regulation of the EZR gene is still poorly understood. To the best of our knowledge, the role of EZR in the progression of CHD remains unclear. In the current study, EZR was revealed to be upregulated in patients with CHD, and as predicted, increased levels of EZR promoted the proliferation and migration of HUVECs. Similar to the effects of the lncRNAs BDNF-AS and NEXN-AS1 on target gene expression [29, 30], knocking down EZR-AS1 decreased the expression level of EZR. Additionally, EZR overexpression reversed the effects of EZR-AS1.
knockdown, indicating that EZR is involved in regulating the biological behaviors of HUVECs. Furthermore, siRNA suppressed the expression of EZR-AS1 while simultaneously raised that of SMYD3, which could reverse the downregulation of EZR mediated by the si-EZR-AS1, which suggested that EZR-AS1 is most likely to regulate EZR expression through SMYD3 signaling in HUVECs; more experiments such as RNA-binding protein immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP) should be done in our next work to further confirm it.

5. Conclusion

In conclusion, and to the best of our knowledge, the present study is the first to report that lncRNA EZR-AS1 is upregulated in severe CHD and that the downregulation of EZR-AS1 inhibits the proliferation, migration, and apoptosis of HUVECs via SMYD3. These data facilitate a deeper understanding of the molecular mechanisms of lncRNA EZR-AS1 in CHD. Therefore, lncRNA EZR-AS1 may be a potential biomarker for the diagnosis and treatment of severe CHD.

Data Availability

The analyzed data sets used and/or analysed during the present study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interests.

Authors’ Contributions

QW designed the research. GY conducted the experimental protocols with assistance from XL, FS, and JH. GY, MT, YX, and SD analyzed the data and wrote the manuscript. All authors reviewed the results and approved the final manuscript.

Acknowledgments

The present study was supported by the Science Technology Platform and Talent Team Plan Projects in Guizhou Province (grant no. 20175405) and the High-level Innovation Talents Training Program in Guizhou Province (grant no. 201604023).

References


